# Social impact bonds for cancer prevention, repaid from avoided treatment costs

Source: https://onco.cc/ideas/idea-fund-social-impact-bonds-prevention/  
OnCo record `idea-fund-social-impact-bonds-prevention` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Investors would fund vaccination and screening campaigns up front and be repaid by health systems only if the campaigns hit verified targets, turning future savings into money for prevention now.

## Summary

Outcome-based contracts in which private or philanthropic investors finance delivery programmes (HPV catch-up vaccination for adults up to 26 or 45, lung screening enrolment among smokers, hepatitis B and C test-and-treat, bowel screening uptake in low-participation areas) and the payer repays with a return only when independently verified coverage or diagnosis-stage targets are met. This shifts the risk of implementation failure from the health system to investors and aligns incentives on measured outcomes. Precedents exist in social care and in tuberculosis and HIV programmes in several countries.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Social impact bonds for cancer prevention achieve their coverage targets in at least two of the first three pilots at a cost per additional person covered no higher than standard grant-funded programmes, and payers repay with a return that is still below the projected downstream savings.
- Rationale: Prevention is chronically under-funded because its savings accrue years later to different budgets; impact bonds move the money forward while keeping accountability on outcomes. Evaluations of health impact bonds show mixed cost-effectiveness but consistent outcome focus, so oncology pilots should be pre-registered with explicit comparisons.
- Proposed test: Run three bonds (HPV catch-up, lung screening, bowel screening) in different regions with independent verification and compare coverage and cost against matched regions using standard funding.
- Maturity: speculative
- Actor: payer

## Sources

- Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022): https://doi.org/10.1038/d41573-022-00030-4

## Connected records

- ideas: [A delivery-science moonshot for prevention we already own](https://onco.cc/ideas/idea-fund-prevention-moonshot/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/), [HPV & HBV vaccination](https://onco.cc/technologies/hpv-vaccine/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- key papers: [Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape](https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/)
- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-social-impact-bonds-prevention.json